Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
That’s how much Eli Lilly’s revenue grew in 2024 ... revision to lower-than-expected sales of tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity.
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...